Radiation and immunotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of treatments for advanced non-small cell lung cancer (NSCLC) that has not been treated before. It combines a type of immunotherapy (envafolimab) with a drug that may slow blood vessel growth (endostar) and a special type of radiation therapy (SRT). This may help shrink tumors and control the cancer for a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have stage IV non-small cell lung cancer (NSCLC), meaning it has spread to other parts of the body.
- Your cancer has not been treated before with chemotherapy, radiation, or immunotherapy (or if you had surgery and chemo, it came back more than 6 months after finishing).
- Your tumor tests positive for a protein called PD-L1 (at least 1% of cells).
- You are in generally good health: able to do daily activities and have adequate kidney, liver, and blood counts.
- You do not have unstable brain metastases, active bleeding, or serious heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving radiation and immunotherapy together to people with advanced lung cancer that hasn't been treated yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of a drug injected directly into the lung tumor and a systemic antibody treatment (likely immunotherapy) for advanced non-small cell lung cancer. It may help if you have a collapsed lung and your cancer has not responded to prior treatment.
This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.